Trang chủ / Kháng Thuốc

Hình Ảnh Minh Họa Các Bước Thực Hiện Thử Nghiệm Ức Chế Neuraminidase


and coalescent analyses". The Lancet, pp. http://dx.doi.org/10.1016/S0140-6736(13)60938-1.

63. Liu Q. , L. L., Sun Z., Chen G., Wen Y., Jiang S. . (2013), "Genomic signature and protein sequence analysis of a novel influenza A (H7N9) virus that causes an outbreak in humans in China". Microbes and Infection, pp. in press.

64. Matsuzaki Y., et al. (2010), "A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir". Virol J, 7, pp. 53.

65. McCauley J. W. and Mahy B. W. (1983), "Structure and function of the influenza virus genome". Biochem J, 211(2), pp. 281-94.

66. Meijer A., L. A., Hungnes O., Lina B., van der Werf S., Schweiger B., et al. (2009), "Oseltamivir-resistant influenza A (H1N1) virus, Europe, 2007–08 season". Emerg Infect Dis, 15(4), pp. 552-560.

67. Menno D. de Jong, M. D., Ph.D., Tran Tan Thanh, M.Sc., Truong Huu Khanh, M.D., Vo Minh Hien, M.D., Gavin J.D. Smith, Ph.D., Nguyen Vinh Chau, M.D., Bach Van Cam, M.D., Phan Tu Qui, M.D., Do Quang Ha, M.D., Ph.D., Yi Guan, M.D., Ph.D., J.S. Malik Peiris, D.Phil., M.D., Tran Tinh Hien, M.D., Ph.D., and Jeremy Farrar, D.Phil., F.R.C.P. (2005), "Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection". N Engl J Med, 353, pp. 2667-2672.

68. Moghadas SM, B. C., Rost G, Wu J. (2008), "Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza". PLoS ONE, 3(3), pp. e1839. doi:10.1371.

69. National Institute of Infectious Diseases. (2013), Antiviral resistance surveillance in Japan. http://www.nih.go.jp/niid/en/influenza-e/2132-flu/flu-dr-e/.

70. Nelson M. I. and Holmes E. C. (2007), "The evolution of epidemic influenza". Nat Rev Genet, 8(3), pp. 196-205.


71. Nelson M. I., E. L., Spiro D. J., Boyne A. R., Bera J., et al.,. (2008), "Molecular Epidemiology of A/H3N2 and A/H1N1 Influenza Virus during a Single Epidemic Season in the United States". PLoS Pathogens, 4(8), pp. e1000133. doi:10.1371.

72. Nelson M. I., V. A. L., Kitikoon P.,Holmes E. C., Gramer M. R., . (2012), "Evolution of Novel Reassortant A/H3N2 Influenza Viruses in North American Swine and Humans, 2009–2011". J. Virol., 86(16), pp. 8872.

73. Nguyen H. T., Fry A. M., and Gubareva L. V. (2012), "Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods". Antivir Ther, 17(1 Pt B), pp. 159-73.

74. Nguyen H. T., et al. (2010), "Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir". Clin Infect Dis, 51(8), pp. 983-4.

75. Nguyen T. D., N. T. V., Vijaykrishna D., WebsterG. R., Guan Y., Peiris J.S. M., Smith J.D. G.,. (2008), "Multiple Sublineages of Influenza A Virus (H5N1), Vietnam, 2005−2007". Emerg Infect Dis., 14(4), pp. 632–636.

76. Nguyen T., R. P., Davis C. T., Do T. H., Balish ., Nguyen H. D., et al.,. (2012), "Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010". Virology, 432, pp. 405– 416.

77. Nguyen T. Y., G. B. S., Nguyen H. T., Tran N. D., Pham D. T., Le T.Q. M., Tran H. N., Bui T. C., Dang T. D., Nguyen T. L., Uyeki M. T., Dennis D., Kile C. J., Kapella K. B., Iuliano A.D., Widdowson M-A., Nguyen T. H.,. (2013), "National surveillance for influenza and influenza-like illness in Vietnam, 2006−2010". Vaccine, 31, pp. 4368–4374.

78. Nukiwa N., S. A., Furuse Y., Shimabukuro K., Odagiri T., Khandaker I., Oshitani H. (2010), "Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction


fragment length polymorphism assay". Journal of Virological Methods, 170, pp. 165-168.

79. Okomo-Adhiambo, M., et al. (2010), "Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective". Viruses, 2(10), pp. 2269-89.

80. Okomo-Adhiambo M., D.-H. J. G., Deyde M. V.,1 Sheu G. T., Xu X., Klimov I. A., Gubareva V. L.,. (2010), "Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance". Antimicrobial Agents and Chemotherapy, 54(5), pp. 1834– 1841.

81. Peasah SK, A.-B. E., Breese J, Meltzer MI, Widdowson MA,. (2013), "Influenza cost and cost-effectiveness studies globally--a review.". Vaccine, 31(46), pp. 5339-48.

82. Pielaka M. R., S. R. J., Chou J. J., . (2009), "Mechanism of drug inhibition and drug resistance of influenza A M2 channel". PNAS, 106(18), pp. 7379– 7384.

83. Ping J., K. L., Forbes E. N., et. al. (2011), "Genomic and Protein Structural Maps of Adaptive Evolution of Human Influenza A Virus to Increased Virulence in the Mouse". PLoS ONE, 6(6), pp. e21740. doi:10.1371/journal.pone.0021740.

84. Potter C. W. (2001), "A history of influenza". Journal of Applied Microbiology, 91(4), pp. 572-579.

85. Prokudina E. N., et al. (2008), "An antigenic epitope of influenza virus nucleoprotein (NP) associated with polymeric forms of NP". Virol J, 5, pp. 37.

86. Rameix-Welti M. A., A. F., Buchy P., Mardy S., Aubin J. T., Veron M., van der Werf S. , Naffakh N.,. (2006), "Natural Variation Can Significantly Alter


the Sensitivity of Influenza A (H5N1) Viruses to Oseltamivir". Antimicrobial Agents and Chemotherapy, 50(11), pp. 3809–3815.

87. Reddy D. (2010), "Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir". J Antimicrob Chemother, 65(Suppl 2), pp. ii35–40.

88. Ronaghi M. (2011), "Pyrosequencing Sheds Light on DNA Sequencing". Genome Res., 11, pp. 3-11.

89. Saito R., et al. (2007), "High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season". J Med Virol, 79(10), pp. 1569-76.

90. Samaan, G., M. McPherson, and J. Partridge. (2013), "A review of the evidence to support influenza vaccine introduction in countries and areas of WHO's Western Pacific Region". PLoS One, 8(7), pp. e70003.

91. Samuel B. Graitcer, L. G., Laurie Kamimoto, Saumil Doshi et al.,. (2011), "Characteristics of Patients with Oseltamivir- Resistant Pandemic (H1N1) 2009, United States". Emerging Infectious Diseases, 17(2), pp. 255.

92. Sandbulte M. R., et al. (2011), "Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses". Proc Natl Acad Sci U S A, 108(51), pp. 20748-53.

93. Sanger F., C. A. R. (1975), "A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase". Journal of Molecular Biology, 94(3), pp. 441-446.

94. Shih C., A., Hsiao T., Ho M., LiW.,. (2007), "Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution". PNAS, 105(15), pp. 6283-6288.

95. Sims L. D., E. T. M., Liu K. K., et.al. (2003), "Avian influenza in Hong Kong 1997-2002". Avian Diseases, 47(3), pp. 832-838.

96. Sleeman, K., et al. (2013), "R292K substitution and drug susceptibility of influenza A(H7N9) viruses". Emerg Infect Dis, 19(9), pp. 1521-4.


97. Smith D. J., et al. (2004), "Mapping the antigenic and genetic evolution of influenza virus". Science, 305(5682), pp. 371-6.

98. Smith G. J., et al. (2009), "Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic". Nature, 459(7250), pp. 1122-5.

99. Subbarao EK, L. W., Murphy BR. (1993), "A single amino acid in the PB2 gene of influenza A virus is a determinant of host range". J Virol., 67(4), pp. 1761-1764.

100. Suki Man-Yan Lee, H.-L. Y. (2012), "Targeting the host or the virus Current and novel concepts for antiviral approaches against influenza virus infection". Antiviral Research, 96, pp. 391-404.

101. Suzuki Y., S. R., Sato I., Zaraket H., Nishikawa M., Tamura T., Dapat C., Caperig-Dapat I., Baranovich T., Suzuki T., Suzuki H.,. (2011), "Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method". J.Clin.Microbiol., 49(1), pp. 125-130.

102. Takano R, K. M., Igarashi M, Le QM, Sekijima M, Ito K, Takada A, Kawaoka Y.,. (2013), "Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses". J Infect Dis., 207(1), pp. 89-97.

103. Tamura D., M. K., Yamazaki M., Fujino M., et al.,. (2009), "Oseltamivir- Resistant Influenza A Viruses Circulating in Japan". J. Clin. Microbiol., 47(5), pp. 1424-1427.

104. Tashiro M., et al. (2009), "Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007". Antivir Ther, 14(6), pp. 751-61.

105. Tong S., et al. (2012), "A distinct lineage of influenza A virus from bats". Proc Natl Acad Sci U S A, 109(11), pp. 4269-74.

106. Vuong D. C., Hoang V. M. P., Nguyen L. K. H., et al. (2012), "The genetic match between vaccine strains and circulating seasonal influenza A viruses


in Vietnam, 2001–2009". Influenza and Other Respiratory Viruses, DOI:10.1111/irv.12038.

107. Wallace R. G., et al. (2007), "A statistical phylogeography of influenza A H5N1". Proc Natl Acad Sci U S A, 104(11), pp. 4473-8.

108. Walter M. B., I. M., Pamela K. Y., Frances MD G., Adolfo G., Noelia M., Daniel R P., Ana S G.-R., Brent S S. (2013), "Influenza A(H1N1)pdm09 virus infection in marine mammals in California". Emerging Microbes and Infections, 2(e40), pp. doi:10.1038.


109.

Wang M., Q. J., Liu Y., Vavricka C. J., Wu Y., Li Q., Gao

"Influenza A Virus N5 Neuraminidase Has an Extended

F. G.,. (2011),

150-Cavity ".


110.

Journal of Virology, 85(16), pp. 8431-8435.

WHO. (2009), "Influenza A(H1N1) virus resistance to


oseltamivir -


2008/2009 influenza season, northern hemisphere".


Có thể bạn quan tâm!

Xem toàn bộ 147 trang tài liệu này.

111. WHO. (2011), "Manual for the laboratory diagnosis and virological surveillance of influenza". pp. 103-114.

112. WHO. (2012), "Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitor (NAI) Genotyping: molecular-based assays".

113. WHO. (2012), "Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitor (NAI) Phenotyping: neuraminidase inhibition assays".

114. WHO. (2012), "Weekly epidemiological record". 39(87), pp. 369-380.

115. WHO. (2013), Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2013. http://www.who.int/influenza/human_animal_interface/EN_GIP_20130426CumulativeNumberH5N1cases.pdf.

116. WHO. (2013), Number of confirmed human cases of avian influenza A(H7N9) reported to WHO.


http://www.who.int/influenza/human_animal_interface/influenza_h7n9/06_ReportWebH7N9Number.pdf.

117. WHO. (2013), Vaccines. http://www.who.int/influenza/vaccines/en/.

118. Wright P. F., N. G., Kawaoka Y.,, (2007), Orthomyxoviridae, in Field's Virology,5th David M. Knipe, P.M.H., Editor, Lippincott Williams & Wilkins: Philadelphia. pp. 1713-1716.

119. Yang J., L. Y., Huang Y., Su C., Lo J. , Ho Y., Yao C., Hsu L., Wu H., Liu M.,. (2011), "Reassortment and Mutations Associated with Emergence and Spread of Oseltamivir-Resistant Seasonal Influenza A/H1N1 Viruses in 2005–2009". PLoS ONE, 6(3), pp. e18177.

120. Yi P. L., X. X., Wharton A. S., Martin R. S., et al.,. (2013), "Evolution of the receptor binding properties of theinfluenza A(H3N2) hemagglutinin". PNAS, 110(7), pp. 2677-2683.

121. Zambon, M. (2011), "Assessment of the burden of influenza in children". Lancet, 378(9807), pp. 1897-8.

122. Zambon M., P. C., (2009), Influenza, in Clinical Virology,6th al., A.J.Z.e., Editor, John Wiley&Sons: Sussex.

123. Zhao D., L. L., Li Y., Jiang Y., Liu L, et al.,. (2012), "Phylogenetic and Pathogenic Analyses of Avian Influenza A H5N1 Viruses Isolated from Poultry in Vietnam". PLoS ONE, 7(11), pp. e50959. doi:10.1371.


PHỤ LỤC 1

1. Hình ảnh minh họa các bước thực hiện thử nghiệm ức chế neuraminidase


1.1 Xác định độ hoạt động của neuraminidase

1.1.1 Hoạt động của neuraminidase qua máy đọc Victor X2


1 1 2 Biểu đồ thể hiện sự hoạt động của neuraminidase và mức độ pha loãng 1

1.1.2 Biểu đồ thể hiện sự hoạt động của neuraminidase và mức độ pha loãng của mỗi vi rút cúm


..... Xem trang tiếp theo?
⇦ Trang trước - Trang tiếp theo ⇨

Ngày đăng: 12/11/2022